Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

Benjamin Diamond, MD, David S Jayabalan, MSc, Roger Pearse, MD PhD, Art Perry, Karen Pekle, Ruben Niesvizky, MD, Adriana C. Rossi, MDMSc

Blood (2017) 130 (Supplement 1): 3102.

https://doi.org/10.1182/blood.V130.Suppl_1.3102.3102

Published: 2017

Journal Articles

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Peter A. Forsberg, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, John N. Allan, MD, Ruben Niesvizky, MD, Tomer Mark, MD MSc

Blood (2016) 128 (22): 4518.

https://doi.org/10.1182/blood.V128.22.4518.4518

Published: 2016

Journal Articles

Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma

Benjamin Diamond, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, David Jayabalan, BSMS, MSc, Arthur Perry, PA, Karen Pekle, NP, Tomer Mark, MD MSc, Ruben Niesvizky, MD

Blood (2016) 128 (22): 4522.

https://doi.org/10.1182/blood.V128.22.4522.4522

Published: 2016

Journal Articles

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Lyubov Neglyad, Jennifer Bourke, RN, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, Kathleen Pogonowski, RN, Linda Tegnestam, RN, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4258.

https://doi.org/10.1182/blood.V126.23.4258.4258

Published: 2015

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Tomer M Mark, MD MSc, Angelique Boyer, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pogonowski, RN, Ekta Aneja, MD, Linda Tegnestam, RN, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4232.

https://doi.org/10.1182/blood.V126.23.4232.4232

Published: 2015

Journal Articles

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott Ely, MD MPH

Blood (2015) 126 (23): 2991.

https://doi.org/10.1182/blood.V126.23.2991.2991

Published: 2015

Journal Articles

The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma

Tomer M Mark, MD MSc, Peter Forsberg, MD, Ihsane Ouansafi, MD, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott A Ely, MD MPH

Blood (2014) 124 (21): 2016.

https://doi.org/10.1182/blood.V124.21.2016.2016

Published: 2014

Journal Articles

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Adriana C Rossi, MD, Ekta Aneja, MBBS, Angelique Boyer, David Jayabalan, BSMS, MSc, Tomer M Mark, MD MSc, Roger Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4754.

https://doi.org/10.1182/blood.V124.21.4754.4754

Published: 2014

Journal Articles

Car-Bird [Carfilzomib, Clarithromycin(Biaxin ® ), Lenalidomide/(Revlimid ® ), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Tomer M Mark, MD MSc, Abbe Schickner, BA, John N. Allan, MD, Adriana C Rossi, MD, Roger Pearse, MD PhD, Linda Tegnestam, RN, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pognowski, RN, David Jayabalan, BSMS, MSc, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4761.

https://doi.org/10.1182/blood.V124.21.4761.4761

Published: 2014

Journal Articles

Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone)

Ekta Aneja, MBBS, Adriana C Rossi, MD, Tomer M Mark, MD MSc, David Jayabalan, BSMS, MSc, Roger Pearse, MD PhD, Karen Pekle, NP, Art Perry, PA, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 5778.

https://doi.org/10.1182/blood.V124.21.5778.5778

Published: 2014

Journal Articles

PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma

Adriana C Rossi, MD, Tomer M Mark, MD, MSc, Kevin Wood, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Stanley Goldsmith, MD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1878.

https://doi.org/10.1182/blood.V122.21.1878.1878

Published: 2013

Journal Articles

Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma

Tomer M Mark, MD, MSc, John N. Allan, MD, Angelique Boyer, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, David Jayabalan, B.S.M.S, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1954.

https://doi.org/10.1182/blood.V122.21.1954.1954

Published: 2013

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Angelique Boyer, Adriana C Rossi, MD, Dennis Kwon, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1955.

https://doi.org/10.1182/blood.V122.21.1955.1955

Published: 2013

Journal Articles

Car-Bird [Carfilzomib, Clarithromycin(Biaxin (R) ), Lenalidomide/(Revlimid (R) ), Dexamethasone) For Newly-Diagnosed Multiple Myeloma

Tomer M Mark, MD, MSc, John N. Allan, MD, Geoffrey Marano, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Linda Tegnestam, RN, Karen Pekle, NP, David Jayabalan, B.S.M.S, Morton Coleman, MD, Scott A Ely, MD, MPH, Ruben Niesvizky, MD

Blood (2013) 122 (21): 3216.

https://doi.org/10.1182/blood.V122.21.3216.3216

Published: 2013

Journal Articles

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

Adriana Rossi, Tomer Mark, David Jayabalan, Paul Christos, Faiza Zafar, Karen Pekle, Roger Pearse, Selina Chen-Kiang, Morton Coleman, Ruben Niesvizky

Blood (2013) 121 (11): 1982–1985.

https://doi.org/10.1182/blood-2012-08-448563

Published: 2013

Includes: Supplemental data

Journal Articles

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Angelique Boyer, Adriana C Rossi, MD, Manan Shah, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, Erlinda A Sacris, RN, June Greenberg, RN, Stephanie Speaker, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2012) 120 (21): 77.

https://doi.org/10.1182/blood.V120.21.77.77

Published: 2012

Journal Articles

ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Melissa Rodriguez, Manan Shah, Ryann Quinn, Jessica Campbell, Ramsey Abdullah, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Patrice Mignott, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 635.

https://doi.org/10.1182/blood.V118.21.635.635

Published: 2011

Journal Articles

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma

Tomer M Mark, MD, MSc, Manan Shah, Melissa Rodriguez, Ryann Quinn, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Patrice Mignott, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 2937.

https://doi.org/10.1182/blood.V118.21.2937.2937

Published: 2011

Journal Articles

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Blood (2008) 111 (3): 1101–1109.

https://doi.org/10.1182/blood-2007-05-090258

Published: 2008

Includes: Supplemental data

Journal Articles

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

Ruben Niesvizky, MD, Scott Ely, MD, MPH, Maurizio DiLiberto, PhD, Hearn J. Cho, MD, PhD, Udi Y. Gelbshtein, David S. Jayabalan, Sangeeta Aggarwal, MD, Janice L. Gabrilove, MD, Roger N. Pearse, MD, PhD, Karen Pekle, RN, ANPC, Faiza Zafar, RPAC, Zoe Goldberg, MD, John P. Leonard, MD, John J. Wright, MD, Selina Chen-Kiang, PhD, Morton Coleman, MD

Blood (2005) 106 (11): 2574.

https://doi.org/10.1182/blood.V106.11.2574.2574

Published: 2005

NARROW

Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Car-Bird [Carfilzomib, Clarithromycin(Biaxin ® ), Lenalidomide/(Revlimid ® ), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone)

PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma

Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

Car-Bird [Carfilzomib, Clarithromycin(Biaxin (R) ), Lenalidomide/(Revlimid (R) ), Dexamethasone) For Newly-Diagnosed Multiple Myeloma

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only